nach oben

Erschienen in:

01.06.2009 | Original Article

Semicarbazide-sensitive amine oxidase activity and total nitrite and nitrate concentrations in serum: novel biochemical markers for type 2 diabetes?

verfasst von: Sandra Fernanda Nunes, Isabel Vitoria Figueiredo, Paulo João Soares, Nuria Espriu Costa, Maria Celeste Lopes, Maria Margarida Caramona

Erschienen in: Acta Diabetologica | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate the activity of semicarbazide-sensitive amine oxidase (SSAO) and the total nitrite and nitrate (NO_x) concentrations in serum from type 2 diabetic patients and control subjects in order to evaluate if they could be used as novel diabetic markers. We studied 38 type 2 diabetic patients and 35 control subjects. Serum samples from those subjects were evaluated by radiochemical methods for SSAO activity using ¹⁴C-benzylamine. Serum NO_x concentrations were obtained as an index of nitric oxide production by the Griess reaction. Serum SSAO activity was higher in type 2 diabetic patients than in control group and serum SSAO in type 2 diabetic correlated with age, serum creatinine and total cholesterol. Serum NO_x levels in type 2 diabetic patients were also significantly higher than those in the control group. Serum NO_x levels in control group correlated with serum SSAO activity. In conclusion, the increase in the SSAO activity and NO_x levels observed in type 2 diabetic patients could be parameters to take in account and play relevant role in diabetes development. SSAO and NO_x are suggested as markers for prognostic of diabetes.

Holt A, Alton G, Scaman CH, Loppnow GR, Szpacenko A, Svendsen I, Palcic MM (1998) Identification of the quinone cofactor in mammalian semicarbazide-sensitive amine oxidase. Biochemistry 37:4946–4957PubMedCrossRef

Tipton KF, Boyce S, O’Sullivan J, Davey GP, Healy J (2004) Monoamine oxidases: certainties and uncertainties. Curr Med Chem 11:1965–1982PubMed

Boomsma F, Bhaggoe UM, van der Houwen AM, van den Meiracker AH (2003) Plasma semicarbazide-sensitive amine oxidase in human (patho) physiology. Biochim Biophys Acta 1647:48–54PubMed

Jakobsson E, Nilsson J, Ogg D, Kleywegt GJ (2005) Structure of human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1. Acta Crystallogr D Biol Crystallogr 61:1550–1562PubMedCrossRef

Boomsma F, Hut H, Bagghoe U, van der Houwen A, van den Meiracker A (2005) Semicarbazide-sensitive amine oxidase (SSAO): from cell to circulation. Med Sci Monit 11:122–126

Gokturk C, Garpenstrand H, Nilsson J, Nordquist J, Oreland L, Forsberg-Nilsson K (2003) Studies on semicarbazide-sensitive amine oxidase in patients with diabetes mellitus and in transgenic mice. Biochim Biophys Acta 1647:88–91PubMed

Stamler JS, Singel DJ, Loscalzo J (1992) Biochemistry of nitric oxide and its redox-activated forms. Science 258:1898–1902PubMedCrossRef

Desvignes C, Bert L, Vinet L, Denoroy L, Renaud B, Lambas-Senas L (1999) Evidence that the neuronal nitric oxide synthase inhibitor 7-nitroindazole inhibits monoamine oxidase in the rat: in vivo effects on extracellular striatal dopamine and 3,4-dihydroxyphenylacetic acid. Neurosci Lett 261:175–178PubMedCrossRef

Girgin SF, Sozmen EY, Ersoz B, Mentes G (2004) Link between monoamine oxidase and nitric oxide. Neurotoxicology 25:91–99CrossRef

10.

Moncada S, Bolanos JP (2006) Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 97:1676–1689PubMedCrossRef

11.

Bode-Boger SM (2006) Effect of l-arginine supplementation on NO production in man. Eur J Clin Pharmacol 62:S91–S99CrossRef

12.

Choi JW (2003) Nitric oxide production is increased in patients with rheumatoid arthritis but does not correlate with laboratory parameters of disease activity. Clin Chim Acta 336:83–87PubMedCrossRef

13.

Izumi N, Nagaoka T, Mori F, Sato E, Takahashi A, Yoshida A (2006) Relation between plasma nitric oxide levels and diabetic retinopathy. Jpn J Ophthalmol 50:465–468PubMedCrossRef

14.

Harrison DG (1994) Endothelial dysfunction in atherosclerosis. Basic Res Cardiol 89:S87–S102

15.

Spack L, Havens PL, Griffith OW (1997) Measurements of total plasma nitrite and nitrate in pediatric patients with the systemic inflammatory response syndrome. Crit Care Med 25:1071–1078PubMedCrossRef

16.

Abou-Seif MA, Youssef AA (2004) Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 346:161–170PubMedCrossRef

17.

Gutteridge JM (1995) Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 41:1819–1828PubMed

18.

Kesavulu MM, Giri R, Kameswara Rao B, Apparao C (2000) Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications. Diabetes Metab 26:387–392PubMed

19.

Parikh CR, Fischer MJ, Estacio R, Schrier RW (2004) Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity. Nephrol Dial Transplant 19:1881–1885PubMedCrossRef

20.

Karadi I, Meszaros Z, Csanyi A, Szombathy T, Hosszufalusi N, Romics L, Magyar K (2002) Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis. Clin Chim Acta 323:139–146PubMedCrossRef

21.

Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 126:131–138PubMedCrossRef

22.

Moshage H, Kok B, Huizenga JR, Jansen PL (1995) Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 41:892–896PubMed

23.

Kuroki T, Isshiki K, King GL (2003) Oxidative stress: the lead or supporting actor in the pathogenesis of diabetic complications. J Am Soc Nephrol 14:S216–S220PubMedCrossRef

24.

Szasz T, Thakali K, Fink GD, Watts SW (2007) A comparison of arteries and veins in oxidative stress: producers, destroyers, function, and disease. Exp Biol Med 232:27–37

25.

Boomsma F, Derkx FH, van den Meiracker AH, Man in ‘t Veld AJ, Schalekamp MA (1995) Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. Clin Sci 88:675–679PubMed

26.

Garpenstrand H, Ekblom J, Backlund LB, Oreland L, Rosenqvist U (1999) Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in type 2 diabetes mellitus complicated by retinopathy. Diabet Med 16:514–521PubMedCrossRef

27.

Gronvall-Nordquist JL, Backlund LB, Garpenstrand H, Ekblom J, Landin B, Yu PH, Oreland L, Rosenqvist U (2001) Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in type 2 diabetes mellitus. J Diabetes Complications 15:250–256PubMedCrossRef

28.

Meszaros Z, Szombathy T, Raimondi L, Karadi I, Romics L, Magyar K (1999) Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride. Metabolism 48:113–117PubMedCrossRef

29.

Yu PH, Lai CT, Zuo DM (1997) Formation of formaldehyde from adrenaline in vivo; a potential risk factor for stress-related angiopathy. Neurochem Res 22:615–620PubMedCrossRef

30.

Girgin FK, Sozmen EY, Ozgonul M, Ersoz B, Mentes G (1999) Link between catecholamine and nitric oxide metabolism. Nitric Oxide 3:496–497PubMedCrossRef

31.

Savino A, Pelliccia P, Schiavone C, Primavera A, Tumini S, Mohn A, Chiarelli F (2006) Serum and urinary nitrites and nitrates and Doppler sonography in children with diabetes. Diabetes Care 29:2676–2681PubMedCrossRef

32.

Ramakrishna V, Jailkhani R (2008) Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol 45:41–46PubMedCrossRef

33.

Maejima K, Nakano S, Himeno M, Tsuda S, Makiishi H, Ito T, Nakagawa A, Kigoshi T, Ishibashi T, Nishio M, Uchida K (2001) Increased basal levels of plasma nitric oxide in type 2 diabetic subjects. Relationship to microvascular complications. J Diabetes Complications 15:135–143PubMedCrossRef

34.

Ozden S, Tatlipinar S, Bicer N, Yaylali V, Yildirim C, Ozbay D, Guner G (2003) Basal serum nitric oxide levels in patients with type 2 diabetes mellitus and different stages of retinopathy. Can J Ophthalmol 38:393–396PubMed

35.

Herman AG, Moncada S (2005) Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur Heart J 26:1945–1955PubMedCrossRef

36.

Yu PH, Zuo DM (1993) Oxidative deamination of methylamine by semicarbazida-sensitive amino oxidase leads to cytotoxic damage in endothelial cells. Possible consequences for diabetes. Diabetes 42:594–603PubMedCrossRef

Titel: Semicarbazide-sensitive amine oxidase activity and total nitrite and nitrate concentrations in serum: novel biochemical markers for type 2 diabetes?
verfasst von: Sandra Fernanda Nunes
Isabel Vitoria Figueiredo
Paulo João Soares
Nuria Espriu Costa
Maria Celeste Lopes
Maria Margarida Caramona
Publikationsdatum: 01.06.2009
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 2/2009
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-008-0070-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Insulin resistance and exercise capacity in male children and adolescents with non-alcholic fatty liver disease

Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus

Bone biomechanical and histomorphometrical investment in type 2 diabetic Goto-Kakizaki rats

Pantalone et al.: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease